- Home
- H vs RPRX Comparison
H vs RPRX Comparison
Compare H & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- H
- RPRX
- Stock Information
- Founded
- H 1957
- RPRX 1996
- Country
- H United States
- RPRX United States
- Employees
- H N/A
- RPRX N/A
- Industry
- H Hotels/Resorts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- H Consumer Discretionary
- RPRX Health Care
- Exchange
- H Nasdaq
- RPRX Nasdaq
- Market Cap
- H 12.8B
- RPRX 14.3B
- IPO Year
- H 2009
- RPRX 2020
- Fundamental
- Price
- H $132.08
- RPRX $32.88
- Analyst Decision
- H Buy
- RPRX Strong Buy
- Analyst Count
- H 17
- RPRX 4
- Target Price
- H $149.41
- RPRX $42.50
- AVG Volume (30 Days)
- H 1.1M
- RPRX 5.8M
- Earning Date
- H 05-01-2025
- RPRX 05-08-2025
- Dividend Yield
- H 0.45%
- RPRX 2.68%
- EPS Growth
- H 23.10
- RPRX 37.60
- EPS
- H 7.89
- RPRX 2.45
- Revenue
- H $3,216,000,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- H $112.35
- RPRX $31.16
- Revenue Next Year
- H $5.56
- RPRX $6.37
- P/E Ratio
- H $16.74
- RPRX $13.41
- Revenue Growth
- H N/A
- RPRX 1.13
- 52 Week Low
- H $102.43
- RPRX $24.05
- 52 Week High
- H $168.20
- RPRX $34.32
- Technical
- Relative Strength Index (RSI)
- H 59.69
- RPRX 51.49
- Support Level
- H $129.94
- RPRX $32.15
- Resistance Level
- H $132.68
- RPRX $32.82
- Average True Range (ATR)
- H 2.96
- RPRX 0.72
- MACD
- H -0.26
- RPRX -0.07
- Stochastic Oscillator
- H 50.00
- RPRX 33.72
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.